NFKB1 and plasma cell myeloma: However, it has been later confirmed that bortezomib can also induce activation of canonical NF-κB signaling in multiple myeloma in vitro.548 Further investigations indicated that this contradictory effect can be prevented by combination therapies such as the use of calpain inhibitors.549